EBIT: Income before interest and taxes.
Madrigal Pharmaceuticals, Inc. (MDGL) had EBIT of $55.99M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$431.27M |
|
$55.44M |
|
$37.81M |
|
$393.45M |
|
$375.28M |
|
$55.99M |
|
$-0.55M |
|
$55.44M |
|
$55.44M |
|
$55.44M |
|
$55.44M |
|
$55.44M |
|
$55.44M |
|
|
EBIT |
$55.99M |
$57.72M |
|
29.25M |
|
30.31M |
|
$1.90 |
|
$1.83 |
|
| Balance Sheet Financials | |
$1.39B |
|
$13.96M |
|
$47.28M |
|
$1.43B |
|
$454.24M |
|
$341.27M |
|
$353.20M |
|
$807.45M |
|
$626.94M |
|
$619.85M |
|
$626.94M |
|
23.22M |
|
| Cash Flow Statement Financials | |
$-23.55M |
|
$320.18M |
|
$15.41M |
|
$203.78M |
|
$515.45M |
|
$311.66M |
|
$108.34M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.05 |
|
-- |
|
-- |
|
0.35 |
|
0.54 |
|
91.23% |
|
12.98% |
|
12.98% |
|
-- |
|
12.86% |
|
12.86% |
|
$-35.58M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
0.31 |
|
1.90 |
|
47.45 |
|
8.84% |
|
8.94% |
|
3.87% |
|
5.73% |
|
$27.00 |
|
$-1.17 |
|
$-0.78 |
|